in asthma has not been established yet. In this study, we investigated the relationship between the level of serum TGF-β and clinical background and other established biomarkers in asthma.
TGF-β and the mode of onset, exacerbation, and fixed airflow limitation was observed, suggesting the detrimental roles of TGF-β in asthma pathology. As other established biomarkers did not show such relationships, TGF-β might serve as an independent biomarker for asthma. Background and Aims: To identify the risk factor of asthma patients in respect of associated comorbidities, we compared the features among patients with asthma, chronic obstructive pulmonary disease (COPD), and controls.
Methods: Data were collected from the Korean National Health and Nutrition Examination Survey. Subjects who completed questionnaires and spirometry were enrolled, and prevalence of comorbidities were compared between subjects with asthma, COPD, and controls.
Results: Data from a total of 9343 adult > 40 years of age who completed questionnaire and PFT were retrieved from KNHANES from 2010 to 2012. Among them, 425 patients (prevalence 4.6 AE 0.3%) had selfreported asthma, 1131 patients (prevalence 12.0 AE 0.5%) were compatible with COPD by spirometer, and 2560 patients (prevalence 17.0 AE 0.5%) had self-reported OA. Age of asthma patients (60.6 AE 0.9) were higher than control groups (54.2 AE 0.2), but lower than COPD patients (64.7 AE 0.4). The prevalence of osteoarthritis was higher in asthma patients (31.9 AE 2.8%) than COPD patients (17.8 AE 1.5%) or control groups (16.2 AE 0.6%). The association of OA with asthma was significant (OR 2.42; 95% CI, 1.87-3.14), but not with COPD (P = 0.33) in univariable analysis. Since age, sex, obesity, and smoking status is known as important confounding factors for both asthma and OA, these variables were adjusted for multivariable analysis. OA was still significantly associated with asthma (adjusted OR 1.85; 95% CI, 1.36-2.51), but not with COPD (P = 0.40) in multivariable analysis. Osteoarthritis medication had no statistically significant influence on asthma development (P = 0.36) in OA patients.
Conclusion:
Osteoarthritis could be one of risk factor of asthma, and attention for history of asthma is required in patients with osteoarthritis. Methods: A retrospective study of all patients admitted with a confirmed diagnosis of asthma from 1st January 2016 to 31st December 2016. Data collection, comprising Asthma Control Test, asthma selfmanagement education, nurse counselling, dosage of inhaled corticosteroids for asthma symptoms and mortality, were compared against the GINA Guidelines.
Results: Of the 132 patients, 43% (n = 57) were males and 57% (n = 75) were females. A majority of the patients 43% (n = 57) were Malays, followed by Chinese 37% (n = 49), followed by Indians 13% (n = 17) and 7% (n = 9) were Others. The mean and median ages of the patients were 46 and 44 respectively.
GINA Recommendation: Asthma Control Test is an objective, robust and validated method for monitoring asthma symptoms severity (Evidence A) Indicator: 100% (n = 132) of the patients had undergone the asthma control test.
GINA Recommendation: Self -management education reduces asthma morbidity in both adult and children Indicator: 100% (n = 132) of the patients had received counselling with self -management plans.
GINA Recommendation: Asthma education and training can be delivered effectively by a range of healthcare providers including pharmacist and nurse (Evidence A) Indicator: 100% (n = 132) of the patients had received intensive asthma counselling.
GINA Recommendation Medium/High dose inhaled corticoid-steroids (Evidence A), or Low dose inhaled corticoid-steroid (Evidence A), for troublesome asthma symptoms most days. Indicator: 100% (n = 132) of the patients with confirmed asthma had medium or high dose inhaled corticoid-steroids or low dose inhaled corticoid-steroids.
GINA Recommendation: Overall mortality <1% in every 250 death worldwide.
Indicator There was no mortality rate during the study period.
The management of patients with asthma was in compliance with the 2016 GINA Guidelines with no reported mortality rate. 
